Ronawk builds programmable infrastructure for mammalian cell manufacturing. Its platform, Bio-OS, integrates materials, workflows, and measurement systems to create controlled environments that enable reproducible and scalable cell production. The company is initially focused on improving mesenchymal stem cell manufacturing for CDMOs in the cell and gene therapy industry, where variability, cost of goods, and slow tech transfer limit the ability to scale advanced therapies. By providing a programmable biological environment, Bio-OS helps manufacturers produce higher-quality cells with greater consistency and portability across production sites. Over time, the platform expands into additional cell systems such as iPSCs, primary cells, and tissue models.
See something off about this company?
Courteney Real
founder
A.J. Mellott
founder
Cell and gene therapies are transforming medicine into treatments produced from living mammalian cells. Biomanufacturing infrastructure, however, was built for microbial fermentation rather than complex mammalian systems. As advanced therapies scale, this mismatch creates high run-to-run variability, elevated cost of goods, and slow tech transfer between production sites. Manufacturing reproducibility has therefore become the primary bottleneck for scaling advanced therapies, particularly in mesenchymal stem cell manufacturing for CDMOs, a market growing from $4.31B in 2024 toward $27.12B by 2033, with approximately $500M annually in MSC manufacturing workflows across North America and Europe.
Ronawk has established early traction through multiple active pilot programs with CDMOs, cancer centers, and life science organizations evaluating Bio-Blocks and the Bio-OS platform. These pilots span applications including MSC manufacturing, iPSC culture, spatial diagnostics, and biologics production, with several collaborators developing new products and services using the technology. As these pilots convert into production workflows and licensing agreements, the company is targeting $10M–$20M ARR within 24 months, supported by the planned $10M Series A-1 to accelerate deployment across CDMO partners.
